Results 281 to 290 of about 346,610 (333)

Heart failure outcomes and empagliflozin effects in patients with heart failure and reduced ejection fraction in sinus rhythm or atrial fibrillation: Data from EMPEROR‐Reduced

European Journal of Heart Failure, EarlyView.
Empagliflozin effects and heart failure outcomes in patients with heart failure with reduced ejection fraction and atrial fibrillation or sinus rhythm. AF, atrial fibrillation; CV, cardiovascular; eGFR, estimated glomerular filtration rate; HHF, hospitalization for heart failure; KCCQ, Kansas City Cardiomyopathy Questionnaire; SE, standard error ...
Michael Böhm, Javed Butler, Amr Abdin, Gerasimos Filippatos, João Pedro Ferreira, Stuart J. Pocock, Martina Brueckmann, Anne Pernille Ofstad, Elke Schueler, Christoph Wanner, Faiez Zannad, Stefan D. Anker, Milton Packer, on behalf of the EMPEROR‐Reduced Trial Committees and Investigators   +13 more
wiley   +1 more source

Lupus Anticoagulant Testing for Diagnosis of Antiphospholipid Syndrome: A Perspective Informed by Local Practice. [PDF]

J Clin Med
Favaloro EJ, Pasalic L.
europepmc   +1 more source

Ferric derisomaltose augments intrinsic skeletal muscle electron transport chain activity in heart failure: A FERRIC‐HF II molecular substudy

European Journal of Heart Failure, EarlyView.
FERRIC‐HF II molecular substudy. FDI, ferric derisomaltose. Aims Skeletal muscle energetic augmentation might be a mechanism via which intravenous iron improves symptoms in heart failure, but no direct measurement of intrinsic mitochondrial function has been performed to support this notion.
Mohamad F. Barakat, Nelson Amaral, Daniel Brayson, George Amin‐Youssef, Huda Abu‐Own, Salma Ayis, Francesco Papalia, Fadi Jouhra, Adam Nabeebaccus, Mark Monaghan, Gerry Carr‐White, Alison Sleigh, Geoffrey Charles‐Edwards, Ajay M. Shah, Graham J. Kemp, Andrew J. Murray, Darlington O. Okonko   +16 more
wiley   +1 more source

Clinical application study of a novel fully automatic erythrocyte osmotic fragility analysis system. [PDF]

Biochem Biophys Rep
Deng Z, Li Y, Xiang Z, Liu Y, Tang J, Zhang S, Zang G, Gao Y, Ma L.   +8 more
europepmc   +1 more source

Beta‐blockers in patients with heart failure with reduced ejection fraction and concomitant chronic obstructive pulmonary disease: Cardiovascular and respiratory outcomes

European Journal of Heart Failure, EarlyView.
In total, 5084 patients from Swedish registries with both heart failure (HF) with reduced ejection fraction (HFrEF) and chronic obstructive pulmonary disease (COPD) were included. Confounding was handled by overlap weighting based on propensity scores for beta‐blocker use. Patients were followed up for 5 years, or until death, emigration from Sweden or
Benedikt N. Beer, Lina Benson, Christian Basile, Benedikt Schrage, Peter Moritz Becher, Stefan Blankenberg, Paulus Kirchhof, Barna Szabó‐Söderberg, Marco Metra, Anne Lindberg, Egidio Imbalzano, Giuseppe M. C. Rosano, Patric Karlström, Peter G.M. Mol, Raffaele Scorza, Lars H. Lund, Felix Lindberg, Gianluigi Savarese   +17 more
wiley   +1 more source

Antithrombotic Medications and Intraocular Hemorrhage Risk in Exudative Age-Related Macular Degeneration.

JAMA Netw Open
Kim MS, Nam S, Lee J, Woo SJ.
europepmc   +1 more source

Assessing the knowledge and awareness of community pharmacists toward direct oral anticoagulant therapy in Saudi Arabia: A cross-sectional study. [PDF]

Medicine (Baltimore)
Basilim A.
europepmc   +1 more source

European Journal of Heart Failure consensus statement. Heart failure pharmacotherapy for patients with heart failure with reduced ejection fraction and concomitant atrial fibrillation: Review of evidence and call to action

European Journal of Heart Failure, EarlyView.
Heart failure (HF) and atrial fibrillation (AF) are major global health challenges with rising prevalence and significant morbidity, mortality, and healthcare burden. Despite advances in HF management, AF remains a critical comorbidity that worsens outcomes and requires ad hoc treatment strategies, increasing the risk of non‐adherence and side effects.
Mark Luedde, Stefan Agewall, Giuseppe Ambrosio, Antoni Bayes‐Genis, Claudio Borghi, Elisabetta Cerbai, Gheorghe A. Dan, Heinz Drexel, Péter Ferdinandy, Erik Lerkevang Grove, Juan Carlos Kaski, Roland Klingenberg, Joao Morais, William Parker, Mark C. Petrie, Bianca Rocca, Anne Grete Semb, Michele Senni, Christian Sohns, Patrick Sulzgruber, Juan Tamargo, Marco Metra, Michael Böhm, Dobromir Dobrev, Samuel Sossalla   +24 more
wiley   +1 more source

Defining the role of systemic autoimmune markers in adult epilepsy: A focus on autoimmune‐associated epilepsy

Epilepsia Open, EarlyView.
Abstract Objective Autoimmune mechanisms are a recognized cause of adult epilepsy, with immunotherapy offering etiology‐specific treatment. Autoimmune‐associated epilepsy is an emerging clinical entity, for which early diagnosis remains challenging and largely depends on neuronal antibody testing.
I‐Ting Lin, Chiehyu Shen, Chi‐Ting Chung, Chang‐Yu Edward Cheng, Pin‐Yu Chen, Tun Jao   +5 more
wiley   +1 more source

Optimal Timing of Oral Anticoagulant Therapy Initiation Post-acute Ischemic Stroke: A Narrative Review. [PDF]

Cureus
Aderinto N, Aljamea LH, Aljamea FH.
europepmc   +1 more source